By Tomas Philipson
March 15, 2024
As part of its “Strike Force on Unfair and Illegal Pricing,” the White House just doubled down on a December plan to allow the federal government to tear up exclusive patent agreements between innovative drug companies and research universities.
The White House says such action would reduce drug prices – and claims it has the authority to do this on patented medicines that benefited, at their earliest stages, from federal research grants.
Read the full article here.